Access the full text.
Sign up today, get DeepDyve free for 14 days.
H. Scher, K. Fizazi, F. Saad, M. Taplin, C. Sternberg, K. Miller, R. Wit, P. Mulders, K. Chi, N. Shore, A. Armstrong, T. Flaig, A. Flechon, P. Mainwaring, M. Fleming, J. Hainsworth, M. Hirmand, B. Selby, L. Seely, J. Bono (2012)
Increased survival with enzalutamide in prostate cancer after chemotherapy.The New England journal of medicine, 367 13
S. Plymate, R. Bhatt, S. Balk (2015)
Taxane resistance in prostate cancer mediated by AR-independent GATA2 regulation of IGF2.Cancer cell, 27 2
J. Bono, C. Logothetis, A. Molina, K. Fizazi, S. North, L. Chu, K. Chi, Robert Jones, O. Goodman, F. Saad, J. Staffurth, P. Mainwaring, S. Harland, T. Flaig, Thomas Hutson, T. Cheng, H. Patterson, J. Hainsworth, C. Ryan, C. Sternberg, S. Ellard, A. Flechon, M. Saleh, M. Scholz, E. Efstathiou, A. Zivi, D. Bianchini, Y. Loriot, N. Chieffo, T. Kheoh, C. Haqq, H. Scher (2011)
Abiraterone and increased survival in metastatic prostate cancer.The New England journal of medicine, 364 21
M. Thadani-Mulero, S. Plymate, P. Giannakakou (2012)
Abstract 285: Androgen receptor splice variants determine taxane sensitivity in prostate cancerCancer Research, 72
E. Mostaghel, B. Marck, S. Plymate, R. Vessella, S. Balk, A. Matsumoto, P. Nelson, B. Montgomery (2011)
Resistance to CYP17A1 Inhibition with Abiraterone in Castration-Resistant Prostate Cancer: Induction of Steroidogenesis and Androgen Receptor Splice VariantsClinical Cancer Research, 17
M. Thadani-Mulero, D. Nanus, P. Giannakakou (2012)
Androgen receptor on the move: boarding the microtubule expressway to the nucleus.Cancer research, 72 18
S. Dehm, L. Schmidt, H. Heemers, R. Vessella, D. Tindall (2008)
Splicing of a novel androgen receptor exon generates a constitutively active androgen receptor that mediates prostate cancer therapy resistance.Cancer research, 68 13
R. Hu, T. Dunn, Shuanzeng Wei, S. Isharwal, R. Veltri, E. Humphreys, Misop Han, A. Partin, R. Vessella, W. Isaacs, G. Bova, Jun Luo (2009)
Ligand-independent androgen receptor variants derived from splicing of cryptic exons signify hormone-refractory prostate cancer.Cancer research, 69 1
P. Kantoff, C. Higano, N. Shore, E. Berger, E. Small, D. Penson, C. Redfern, A. Ferrari, R. Dreicer, R. Sims, Yi Xu, M. Frohlich, P. Schellhammer (2010)
Sipuleucel-T immunotherapy for castration-resistant prostate cancer.The New England journal of medicine, 363 5
Menglei Zhu, C. Horbinski, M. Garzotto, D. Qian, T. Beer, N. Kyprianou (2010)
Tubulin-targeting chemotherapy impairs androgen receptor activity in prostate cancer.Cancer research, 70 20
E. Eisenhauer, P. Therasse, J. Bogaerts, L. Schwartz, D. Sargent, R. Ford, J. Dancey, S. Arbuck, S. Gwyther, M. Mooney, Lawrence Rubinstein, L. Shankar, L. Dodd, Robert Kaplan, D. Lacombe, J. Verweij (2009)
New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).European journal of cancer, 45 2
I. Tannock, R. Wit, W. Berry, J. Horti, A. Płużańska, K. Chi, S. Oudard, C. Théodore, N. James, I. Turesson, M. Rosenthal, M. Eisenberger (2004)
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.The New England journal of medicine, 351 15
E. Basch, D. Loblaw, T. Oliver, M. Carducci, Ronald Chen, J. Frame, K. Garrels, S. Hotte, M. Kattan, D. Raghavan, F. Saad, M. Taplin, C. Walker-Dilks, James Williams, E. Winquist, C. Bennett, Ted Wootton, R. Rumble, S. Dusetzina, Katherine Virgo (2014)
Systemic therapy in men with metastatic castration-resistant prostate cancer:American Society of Clinical Oncology and Cancer Care Ontario clinical practice guideline.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 32 30
R. Hu, Changxue Lu, E. Mostaghel, S. Yegnasubramanian, Meltem Gurel, C. Tannahill, J. Edwards, W. Isaacs, P. Nelson, Eric Bluemn, S. Plymate, Jun Luo (2012)
Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer.Cancer research, 72 14
Yingming Li, S. Chan, L. Brand, T. Hwang, K. Silverstein, S. Dehm (2013)
Androgen receptor splice variants mediate enzalutamide resistance in castration-resistant prostate cancer cell lines.Cancer research, 73 2
Chris Parker, Sten Nilsson, Sten Nilsson, D. Heinrich, S. Helle, J. O’Sullivan, S. Fosså, Aleš Chodacki, P. Wiechno, John Logue, Mihalj Seke, Anders Widmark, D. Johannessen, Peter Hoskin, D. Bottomley, Nicholas James, Arne Solberg, Isabel Syndikus, J. Kliment, S. Wedel, S. Boehmer, M. Dall'oglio, L. Franzén, R. Coleman, N. Vogelzang, C. O'Bryan-Tear, K. Staudacher, Jose Garcia-Vargas, Ming-wei Shan, Ø. Bruland, O. Sartor (2013)
Alpha emitter radium-223 and survival in metastatic prostate cancer.The New England journal of medicine, 369 3
E. Antonarakis, Changxue Lu, Hao Wang, Brandon Luber, M. Nakazawa, J. Roeser, Yan Chen, Tabrez Mohammad, Yidong Chen, Helen Fedor, T. Lotan, Qizhi Zheng, A. Marzo, J. Isaacs, W. Isaacs, R. Nadal, C. Paller, S. Denmeade, M. Carducci, M. Eisenberger, Jun Luo (2014)
AR-V7 and resistance to enzalutamide and abiraterone in prostate cancer.The New England journal of medicine, 371 11
T. Karantanos, C. Evans, B. Tombal, T. Thompson, R. Montironi, W. Isaacs (2015)
Understanding the mechanisms of androgen deprivation resistance in prostate cancer at the molecular level.European urology, 67 3
H. Scher, S. Halabi, I. Tannock, M. Morris, C. Sternberg, M. Carducci, M. Eisenberger, C. Higano, G. Bubley, R. Dreicer, D. Petrylak, P. Kantoff, E. Basch, W. Kelly, W. Figg, E. Small, T. Beer, G. Wilding, Alison Martin, M. Hussain (2008)
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 7
L. Gan, Shuai Chen, Yuwei Wang, A. Watahiki, L. Bohrer, Zhen Sun, Yuzhuo Wang, Haojie Huang (2009)
Experimental Therapeutics , Molecular Targets , and Chemical Biology Inhibition of the Androgen Receptor as a Novel Mechanism of Taxol Chemotherapy in Prostate Cancer
M Thadani-Mulero, L Portella, S Sun (2014)
Androgen receptor splice variants determine taxane sensitivity in prostate cancer., 74
R. Soest, E. Morrée, C. Kweldam, C. Ridder, E. Wiemer, R. Mathijssen, R. Wit, W. Weerden (2015)
Targeting the Androgen Receptor Confers In Vivo Cross-resistance Between Enzalutamide and Docetaxel, But Not Cabazitaxel, in Castration-resistant Prostate Cancer.European urology, 67 6
B. Seruga, A. Ocaña, I. Tannock (2011)
Drug resistance in metastatic castration-resistant prostate cancerNature Reviews Clinical Oncology, 8
L Gan, S Chen, Y Wang (2009)
Inhibition of the androgen receptor as a novel mechanism of taxol chemotherapy in prostate cancer., 69
B. Kirby, M. Jodari, M. Loftus, G. Gakhar, E. Pratt, Chantal Chanel-Vos, Jason Gleghorn, S. Santana, He Liu, James Smith, Vicente Navarro, S. Tagawa, N. Bander, D. Nanus, P. Giannakakou (2012)
Functional Characterization of Circulating Tumor Cells with a Prostate-Cancer-Specific Microfluidic DevicePLoS ONE, 7
Renée Leeuw, L. Berman-Booty, M. Schiewer, S. Ciment, R. Den, A. Dicker, W. Kelly, E. Trabulsi, C. Lallas, L. Gomella, K. Knudsen (2015)
Novel Actions of Next-Generation Taxanes Benefit Advanced Stages of Prostate CancerClinical Cancer Research, 21
A. Armstrong, M. Eisenberger, S. Halabi, S. Oudard, D. Nanus, D. Petrylak, A. Sartor, H. Scher (2012)
Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.European urology, 61 3
J. Bono, S. Oudard, M. Ozguroglu, S. Hansen, J. Machiels, I. Kocák, G. Gravis, I. Bodrogi, Mary Mackenzie, L. Shen, M. Roessner, Sunil Gupta, A. Sartor (2010)
Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trialThe Lancet, 376
M. Darshan, M. Loftus, M. Thadani-Mulero, B. Levy, D. Escuin, X. Zhou, A. Gjyrezi, Chantal Chanel-Vos, R. Shen, S. Tagawa, N. Bander, D. Nanus, P. Giannakakou (2011)
Taxane-induced blockade to nuclear accumulation of the androgen receptor predicts clinical responses in metastatic prostate cancer.Cancer research, 71 18
ImportanceWe previously showed that detection of androgen receptor splice variant 7 (AR-V7) in circulating tumor cells (CTCs) from men with castration-resistant prostate cancer (CRPC) was associated with primary resistance to enzalutamide and abiraterone therapy, but the relevance of AR-V7 status in the context of chemotherapy is unknown. ObjectiveTo investigate whether AR-V7–positive patients would retain sensitivity to taxane chemotherapy and whether AR-V7 status would have a differential impact on taxane-treated men compared with enzalutamide- or abiraterone-treated men. Design, Setting, and ParticipantsWe examined CTCs for AR-V7 mRNA using a reverse-transcription polymerase chain reaction assay. From January 2013 to July 2014, we prospectively enrolled patients with metastatic CRPC initiating taxane chemotherapy (docetaxel or cabazitaxel) at a single academic institution (Johns Hopkins). Our prespecified statistical plan required a sample size of 36 taxane-treated men. Main Outcomes and MeasuresWe evaluated associations between AR-V7 status and prostate-specific antigen (PSA) response rates, PSA progression-free survival (PSA PFS), and clinical and/or radiographic progression-free survival (PFS). After incorporating updated data from our prior study of 62 patients treated with enzalutamide or abiraterone, we also investigated the interaction between AR-V7 status (positive or negative) and treatment type (taxane vs enzalutamide or abiraterone). ResultsOf 37 taxane-treated patients enrolled, 17 (46%) had detectable AR-V7 in CTCs. Prostate-specific antigen responses were achieved in both AR-V7–positive and AR-V7–negative men (41% vs 65%; P = .19). Similarly, PSA PFS (hazard ratio [HR], 1.7, 95% CI, 0.6-5.0; P = .32) and PFS (HR, 2.7, 95% CI, 0.8-8.8; P = .11) were comparable in AR-V7–positive and AR-V7–negative patients. A significant interaction was observed between AR-V7 status and treatment type (P < .001). Clinical outcomes were superior with taxanes compared with enzalutamide or abiraterone therapy in AR-V7–positive men, whereas outcomes did not differ by treatment type in AR-V7–negative men. In AR-V7–positive patients, PSA responses were higher in taxane-treated vs enzalutamide- or abiraterone-treated men (41% vs 0%; P < .001), and PSA PFS and PFS were significantly longer in taxane-treated men (HR, 0.19 [95% CI, 0.07-0.52] for PSA PFS, P = .001; HR, 0.21 [95% CI, 0.07-0.59] for PFS, P = .003). Conclusions and RelevanceDetection of AR-V7 in CTCs from men with metastatic CRPC is not associated with primary resistance to taxane chemotherapy. In AR-V7–positive men, taxanes appear to be more efficacious than enzalutamide or abiraterone therapy, whereas in AR-V7–negative men, taxanes and enzalutamide or abiraterone may have comparable efficacy. Circulating tumor cell–based AR-V7 detection may serve as a treatment selection biomarker in CRPC.
JAMA Oncology – American Medical Association
Published: Aug 1, 2015
Read and print from thousands of top scholarly journals.
Already have an account? Log in
Bookmark this article. You can see your Bookmarks on your DeepDyve Library.
To save an article, log in first, or sign up for a DeepDyve account if you don’t already have one.
Copy and paste the desired citation format or use the link below to download a file formatted for EndNote
Access the full text.
Sign up today, get DeepDyve free for 14 days.
All DeepDyve websites use cookies to improve your online experience. They were placed on your computer when you launched this website. You can change your cookie settings through your browser.